Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Human epidermal growth factor receptor 2 (HER2)-low breast cancer has recently emerged
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
as a targetable subset of breast tumors, based on the evidence from clinical trials of novel …
A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers
K Liu, M Li, Y Li, Y Li, Z Chen, Y Tang, M Yang… - Molecular Cancer, 2024 - Springer
While strategies such as chemotherapy and immunotherapy have become the first-line
standard therapies for patients with advanced or metastatic cancer, acquired resistance is …
standard therapies for patients with advanced or metastatic cancer, acquired resistance is …
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
Background Outcomes in patients with hormone receptor–positive metastatic breast cancer
worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has …
worsen after one or more lines of endocrine-based therapy. Trastuzumab deruxtecan has …
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
The mechanisms of action of and resistance to trastuzumab deruxtecan (T-DXd), an anti-
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
HER2–drug conjugate for breast cancer treatment, remain unclear. The phase 2 DAISY trial …
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
Trastuzumab deruxtecan (T-DXd) intracranial activity has been observed in small or
retrospective patient cohorts with human epidermal growth factor receptor 2–positive …
retrospective patient cohorts with human epidermal growth factor receptor 2–positive …
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
Trastuzumab deruxtecan (T-DXd) demonstrated significantly improved efficacy over
trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We …
trastuzumab emtansine (T-DM1) in DESTINY-Breast03 (median follow-up, 28 months). We …
Mechanisms of resistance to antibody-drug conjugates
The treatment of cancer patients has dramatically changed over the past decades with the
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …
advent of monoclonal antibodies, immune-checkpoint inhibitors, bispecific antibodies, and …
Management of patients with advanced-stage HER2-positive breast cancer: current evidence and future perspectives
Amplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …
15–20% of invasive breast cancers and is associated with an aggressive phenotype and …
crVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer
Aims With the wide application of trastuzumab deruxtecan (T-DXd), the survival of HER2-low
breast cancer patients is dramatically improved. However, resistance to T-DXd still exists in …
breast cancer patients is dramatically improved. However, resistance to T-DXd still exists in …
[HTML][HTML] 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)
This manuscript describes the Advanced Breast Cancer (ABC) international consensus
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …
guidelines updated at the last two ABC international consensus conferences (ABC 6 in …